# Monoclonal antibodies: Materials

Source page: https://www.materialinsights.org/technologies/monoclonal_antibodies/tech-materials/

#### Materials it needs

The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is
 Needs

- [Su Sugar](https://www.materialinsights.org/commodities/sugar/) criticality low The antibody-making cells are grown in nutrient media fed with sugars.
- [Lys Amino acids (lysine, methionine)](https://www.materialinsights.org/chemicals/amino_acids/) criticality low Cells need amino acids in their growth medium to build the antibody protein.
 Uses

- [Exc Pharmaceutical excipients](https://www.materialinsights.org/chemicals/excipients/) criticality low Finished antibody medicines are formulated with stabilisers and buffers so they keep in the vial.

as of 2026-11-11. No source gives amounts per dose; the inputs are common, so criticality is the writer's judgement.

#### Critical materials

The materials whose supply could hold it back

- No raw material is likely to hold antibody medicines back: the cells are fed common sugars, salts and amino acids.
- The constraints are capacity and regulation: production needs licensed biologics plants, and each medicine is approved separately.
- Market concentration is high: in 2018 seven companies dominated the therapeutic antibody market, led by Genentech with about 30.8% and AbbVie with 20.0% ^[2].

as of 2026-11-11

#### Sources

1. [Development of therapeutic antibodies for the treatment of diseases](https://pmc.ncbi.nlm.nih.gov/articles/PMC6939334) Journal of Biomedical Science 27: 1 (Lu, Hwang, Liu, Lee, Tsai, Li and Wu), on PubMed Central, 2020

## Other sections

- [Summary](https://www.materialinsights.org/technologies/monoclonal_antibodies/index.md)
- [Overview](https://www.materialinsights.org/technologies/monoclonal_antibodies/tech-overview/index.md)
- [Science](https://www.materialinsights.org/technologies/monoclonal_antibodies/tech-science/index.md)
- [Evolution](https://www.materialinsights.org/technologies/monoclonal_antibodies/tech-evolution/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/monoclonal_antibodies/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/monoclonal_antibodies/tech-industries/index.md)
